This page shows the latest gantenerumab news and features for those working in and with pharma, biotech and healthcare.
Roche also had updated results from a previously-reported trial of its gantenerumab candidate that failed to show a benefit on cognition.
That view took a knock last December however when Roche announced it was halting a phase III trial of its gantenerumab candidate in prodromal Alzheimer's after an independent panel concluded
of patients, with a host of failed projects including most recently Roche's gantenerumab.
The Swiss pharma company will discontinue a phase III programme investigating its anti-amyloid medicine gantenerumab in people in the early stages of Alzheimer's after an analysis of interim data. ... Roche has not given up on gantenerumab completely,
One of the drugs to fail at this late stage – Lilly's solanezumab – is currently being tested in an Alzheimer's prevention study alongside Roche's dementia hope gantenerumab. ... Like many other investigational Alzheimer's treatments solanezumab and
Other Alzheimer's antibodies include Roche's gantenerumab and Lilly's solanezumab.
More from news
Approximately 2 fully matching, plus 7 partially matching documents found.
Crenezumab, gantenerumab, and solanezumab are all involved in additional prospective longitudinal investigations – the Alzheimer’ s Prevention Initiative (Phase 2), the Dominantly Inherited Alzheimer Network study (Phase 2/3), and the
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...